FY2026 EPS Estimates for Oncobiologics Reduced by Analyst

Oncobiologics, Inc. (NASDAQ:OTLK) – Research analysts at HC Wainwright dropped their FY2026 earnings per share estimates for shares of Oncobiologics in a research note issued on Wednesday, February 18th. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings of ($0.42) per share for the year, down from their previous estimate of ($0.28). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Oncobiologics’ current full-year earnings is ($2.27) per share. HC Wainwright also issued estimates for Oncobiologics’ Q4 2026 earnings at ($0.05) EPS, Q1 2027 earnings at ($0.06) EPS, Q2 2027 earnings at ($0.05) EPS, Q3 2027 earnings at ($0.05) EPS, Q4 2027 earnings at ($0.04) EPS and FY2027 earnings at ($0.21) EPS.

Several other research analysts have also recently commented on the company. Ascendiant Capital Markets boosted their price target on Oncobiologics from $8.00 to $10.00 and gave the stock a “buy” rating in a research note on Monday, December 22nd. Wall Street Zen lowered Oncobiologics from a “hold” rating to a “sell” rating in a research report on Saturday, January 3rd. Chardan Capital reiterated a “neutral” rating on shares of Oncobiologics in a research note on Wednesday. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Oncobiologics in a research report on Monday, December 29th. One analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Oncobiologics presently has a consensus rating of “Hold” and an average price target of $6.50.

Oncobiologics Trading Down 4.9%

Shares of OTLK stock opened at $0.41 on Friday. The firm has a fifty day simple moving average of $0.90 and a 200-day simple moving average of $1.31. The company has a market capitalization of $34.32 million, a PE ratio of -0.16 and a beta of 0.10. Oncobiologics has a twelve month low of $0.38 and a twelve month high of $3.39.

Oncobiologics (NASDAQ:OTLK) last issued its quarterly earnings data on Tuesday, February 17th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.05). The business had revenue of ($1.21) million for the quarter, compared to the consensus estimate of $3.14 million.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Russell Investments Group Ltd. grew its position in shares of Oncobiologics by 865.2% during the 2nd quarter. Russell Investments Group Ltd. now owns 24,477 shares of the company’s stock valued at $39,000 after buying an additional 21,941 shares during the last quarter. AQR Capital Management LLC grew its holdings in shares of Oncobiologics by 42.7% during the first quarter. AQR Capital Management LLC now owns 84,671 shares of the company’s stock valued at $103,000 after purchasing an additional 25,351 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its position in shares of Oncobiologics by 74.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 103,524 shares of the company’s stock worth $126,000 after purchasing an additional 44,063 shares during the period. 11.20% of the stock is currently owned by institutional investors.

Key Headlines Impacting Oncobiologics

Here are the key news stories impacting Oncobiologics this week:

• Positive Sentiment: Brookline Capital Acquisition raised its Q4 2026 EPS estimate for OTLK to ($0.18) from ($0.22), narrowing the expected quarterly loss — a modest positive signal that one shop sees slightly better near-term performance.
• Neutral Sentiment: HC Wainwright reiterated a “Neutral” rating on Oncobiologics while publishing updated quarterly/annual estimates; the firm remains cautious but did not upgrade or downgrade the stock. HC Wainwright Reaffirms “Neutral” Rating for Oncobiologics (NASDAQ:OTLK)
• Neutral Sentiment: Chardan Capital reiterated its “Neutral” rating on OTLK, signaling no near-term change in analyst stance despite the earnings miss and estimate revisions. Chardan Capital Reiterates Neutral Rating for Oncobiologics (NASDAQ:OTLK)
• Negative Sentiment: HC Wainwright cut FY2026 estimates significantly (FY2026 EPS to ($0.42) from ($0.28)) and trimmed FY2027 to ($0.21) from ($0.19), and nudged Q4 2026 to a larger expected loss — these downward revisions signal weaker near-term profitability expectations and add selling pressure.
• Negative Sentiment: Brookline Capital Acquisition lowered multiple 2026 quarterly and full‑year EPS forecasts (e.g., FY2026 now ($0.79) vs. prior ($0.74); Q2/Q3 2026 also reduced), indicating broader analyst downside revisions across the board.
• Negative Sentiment: Oncobiologics’ recent reported miss (Feb. 17: EPS ($0.22) vs est. ($0.17); revenue sharply below expectations) remains the primary near-term catalyst weighing on the stock—analyst cuts followed the miss and are likely driving continued downward price pressure.

About Oncobiologics

Oncobiologics, Inc is a clinical-stage biopharmaceutical company specializing in the development of biosimilar therapeutics for cancer and autoimmune diseases. Leveraging recombinant DNA technology and advanced formulation platforms, the company aims to create high-quality, cost-effective alternatives to originator biologic drugs. Oncobiologics’ research focus includes monoclonal antibodies and growth factors that support oncology treatment and immunomodulation.

Founded in 2005 and headquartered in Marlborough, Massachusetts, Oncobiologics maintains research facilities in the Greater Boston area and an integrated manufacturing site in Hyderabad, India, through its wholly owned subsidiary.